Infliximab

Infliximab is covered for multiple labeled autoimmune and inflammatory conditions (moderately to severely active Crohn's disease, fistulizing Crohn's, psoriatic arthritis, rheumatoid arthritis with methotrexate, ankylosing spondylitis, chronic severe plaque psoriasis, and moderately to severely active ulcerative colitis) when patients have inadequate response or intolerance to conventional therapies; standard induction is at weeks 0, 2 and 6 with maintenance approximately every 8 weeks for responders. Coverage includes several specified off‑label uses (reactive arthritis, hidradenitis suppurativa, Behçet's disease, chronic pulmonary sarcoidosis) subject to additional documented prerequisites; infliximab is not covered with concomitant biologic DMARDs or JAK inhibitors and is contraindicated in class III/IV CHF or untreated active/latent tuberculosis.

"Infliximab is covered to induce and maintain clinical remission in adult and pediatric patients with moderately to severely active Crohn's disease who have had an inadequate response to conventiona..."